ITUS will Present Data at the American Association of Cancer Research (AACR) Annual Meeting

SAN JOSE, Calif., March 12, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), today announced that it will present data from its ongoing study utilizing Cchek™, ITUS's artificial intelligence (AI) driven early cancer detection technology.  The presentation will be made at the annual meeting of the American Association of Cancer Research (AACR) in Chicago, Illinois.  The meeting will be held April 14-18, 2018 and will be attended by world leading experts across the field of cancer research.  All abstracts will be viewable by registered attendees beginning March 14, 2018.  To receive a copy of the presentation, please email your request to starting April 19, 2018 and include your name, title, and contact information.

ITUS Logo (PRNewsfoto/ITUS Corporation)

The presentation will focus on ITUS' proprietary Cchek™ platform featuring new data and insights into this early cancer detection technology.  Cchek™ combines the immunophenotyping of white blood cells using flow cytometry with a proprietary neural network, a type of artificial intelligence (AI), to detect the presence of solid tumors from a blood sample.  Identifying and measuring circulating myeloid-derived suppressor cells (MDSCs), a group of immunosuppressive white blood cells, is the foundation of this technology.

"We are pleased to be presenting our data at the annual AACR meeting, the largest yearly scientific meeting for cancer researchers," stated Dr. Amit Kumar, President and CEO of ITUS Corporation.  "As we continue to advance our technology, we expect that premier scientific conferences will enable us to educate the scientific community and the broader cancer community about our findings."

American Association of Cancer Research (AACR)
The American Association of Cancer Research (AACR) ( is a 501(c)(3) public charity headquartered in Philadelphia, PA.  The mission of the AACR is to prevent and cure cancer through research, education, communication and collaboration.  Through its programs and services, the AACR fosters cancer research and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer causes, prevention, diagnosis and treatment throughout the world.  The theme for the 2018 AACR Annual Meeting is "Driving Innovative Cancer Science to Patient Care."

ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer.  Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the CchekTM platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy.  Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.  ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization.  Additional information is available at

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.



Cision View original content with multimedia:

SOURCE ITUS Corporation